Yale spin­out re-en­gi­neers an im­munother­a­py GSK, oth­ers once aban­doned

Be­gin­ning in 2004, Glax­o­SmithK­line ran 5 dif­fer­ent tri­als to see if giv­ing pa­tients a mol­e­cule called IL-18 could treat their can­cers. An ear­ly form of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.